{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T07:43:32Z","timestamp":1770018212500,"version":"3.49.0"},"reference-count":69,"publisher":"Oncology Nursing Society (ONS)","issue":"0","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2011,8,1]]},"DOI":"10.1188\/11.cjon.s1.66-76","type":"journal-article","created":{"date-parts":[[2011,8,4]],"date-time":"2011-08-04T21:42:03Z","timestamp":1312494123000},"page":"66-76","source":"Crossref","is-referenced-by-count":30,"title":["Renal Complications in Multiple Myeloma and Related Disorders"],"prefix":"10.1188","volume":"15","author":[{"given":"Beth M.","family":"Faiman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Mangan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacy","family":"Spong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph D.","family":"Tariman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2011,8,3]]},"reference":[{"key":"1","unstructured":"Attal, M., Cristini, C., Marit, G., Caillot, T., Facon, C., Hullin, P., \u2026 Harousseau, J.L. (2010). Lenalidomide maintenance after transplantation for myeloma. Retrieved from <a target=\"_blank\" href='http:\/\/www.asco.org\/ascov2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=41503'>http:\/\/www.asco.org\/ascov2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=41503<\/a>"},{"key":"2","unstructured":"Attal, M., Harousseau, J.L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.G., \u2026 Bataille, R. (2002). <i>Double autologous transplantation improves survival of multiple myeloma patients: Final analysis of a prospective randomized study of the Intergroupe Francophone du Myelome.<\/i> Retrieved from <a target=\"_blank\" href='http:\/\/www.cancereducation.com\/CancerSysPagesNB\/abstracts\/mmrf\/31\/AAVW1.pdf'>http:\/\/www.cancereducation.com\/CancerSysPagesNB\/abstracts\/mmrf\/31\/AAVW1.pdf<\/a>"},{"key":"3","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem cell transplantation for multiple myeloma","volume":"349","author":"M. Attal","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"4","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"M. Attal","year":"2006","journal-title":"Blood"},{"key":"5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"M. Attal","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"6","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","article-title":"Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution","volume":"158","author":"J. Blade","year":"1998","journal-title":"Archives of Internal Medicine"},{"key":"7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.beha .2005.01.013","article-title":"Renal, hematologic, and infectious complications in multiple myeloma","volume":"18","author":"J. Blade","year":"2005","journal-title":"Best Practice and Research. Clinical Haematology"},{"key":"8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3816\/CLM.2008.n.051","article-title":"Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: Efficacy and safety in patients with renal function impairment","volume":"8","author":"J. Blade","year":"2008","journal-title":"Clinical Lymphoma and Myeloma"},{"key":"9","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1373\/clinchem.2009.123828","article-title":"Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa\/lambda ratios","volume":"55","author":"A. Bradwell","year":"2009","journal-title":"Clinical Chemistry"},{"key":"10","first-page":"65","article-title":"Effects of nonsteroidal anti-inflammatory drugs on renal function: Focus of cyclooxygenase-2-selective inhibition","volume":"107","author":"D. Brater","year":"1999","journal-title":"AJN"},{"key":"11","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1053\/j.ajkd.2004.12.020","article-title":"Fanconi's Syndrome induced by a monoclonal V3 light chain in Waldenstr\u00f6m's macroglobulinemia","volume":"45","author":"F. Bridoux","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"key":"12","unstructured":"Celgene Corp. (2004). Alkeran\u00ae (melphalan) [Product information]. Summit, NJ: Author"},{"key":"13","unstructured":"Celgene Corp. (2010a). <i>Revlimid\u00ae (lenalidomide)<\/i> [Product information]. Warren, NJ: Author."},{"key":"14","unstructured":"Celgene Corp. (2010b). <i>Thalomid\u00ae (thalidomide)<\/i> [Product information]. Summit, NJ: Author."},{"key":"15","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1182\/blood-2006-09-046409","article-title":"Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study","volume":"109","author":"A. Chanan-Khan","year":"2007","journal-title":"Blood"},{"key":"16","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1080\/10428190902912460","article-title":"Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: Results of a phase II clinical trial","volume":"50","author":"A. Chanan-Khan","year":"2009","journal-title":"Leukemia and Lymphoma"},{"key":"17","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ki.2008.117","article-title":"Plasma exchange for myeloma kidney: Cast(s) away?","volume":"73","author":"W. Clark","year":"2008","journal-title":"Kidney International"},{"key":"18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-143-11-200512060-00005","article-title":"Plasma exchange when myeloma presents as acute renal failure: A randomized, controlled trial","volume":"143","author":"W. Clark","year":"2005","journal-title":"Annals of Internal Medicine"},{"issue":"7","key":"19","article-title":"Economic and clinical impact of multiple myeloma to managed care","volume":"14","author":"R. Cook","year":"2008","journal-title":"Journal of Managed Care Pharmacy"},{"key":"20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/pgmj.65.763.302","article-title":"The cost of chronic dialysis in multiple myeloma","volume":"65","author":"R. Coward","year":"1989","journal-title":"Postgraduate Medicine Journal"},{"key":"21","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1200\/JCO.2010.30.8791","article-title":"The efficacy and safety of lenalidomide plus dexamethasone in relapsed and\/or refractory multiple myeloma patients with impaired renal function","volume":"116","author":"M. Dimopoulos","year":"2010","journal-title":"Cancer"},{"key":"22","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"M. Dimopoulos","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"23","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1038\/leu.2008.131","article-title":"Pathogenesis and treatment of renal failure in multiple myeloma","volume":"22","author":"M. Dimopoulos","year":"2008","journal-title":"Leukemia"},{"key":"24","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"M. Dimopoulos","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"A. Dispenzieri","year":"2009","journal-title":"Leukemia"},{"key":"26","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/leu.2008.307","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"A. Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"27","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1182\/blood.V97.9.2900","article-title":"Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma","volume":"97","author":"M. Drayson","year":"2001","journal-title":"Blood"},{"issue":"3","key":"28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1188\/08.CJON.S1.53-62","article-title":"Consensus statement for the management of steroid-associated side effects in patients with multiple myeloma","volume":"12","author":"B. Faiman","year":"2008","journal-title":"Clinical Journal of Oncology Nursing"},{"key":"29","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/ki.2009.307","article-title":"Health-related quality of life and the CKD patient: Challenges for the nephrology community","volume":"76","author":"F. Finkelstein","year":"2009","journal-title":"Kidney International"},{"issue":"6","key":"30","article-title":"Type 2 diabetes: Which interventions best reduce absolute risks of adverse events?","volume":"58","author":"B. Firestone","year":"2009","journal-title":"Journal of Family Practice"},{"key":"31","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.4065\/77.12.1278","article-title":"Diagnosing primary amyloidosis","volume":"77","author":"M. Gertz","year":"2002","journal-title":"Mayo Clinic Proceedings"},{"key":"32","doi-asserted-by":"crossref","first-page":"835","DOI":"10.7326\/0003-4819-143-11-200512060-00013","article-title":"Managing myeloma kidney","volume":"143","author":"M. Gertz","year":"2005","journal-title":"Annals of Internal Medicine"},{"key":"33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2004.03.027","article-title":"Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay","volume":"44","author":"S. Hallan","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"key":"34","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1097\/01.ASN.0000095249.99803.85","article-title":"Risk factors for chronic kidney disease: A prospective study of 23,534 men and women in Washington County, Maryland","volume":"14","author":"M. Haroun","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"key":"35","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study","volume":"91","author":"J. Harousseau","year":"2006","journal-title":"Haematologica"},{"key":"36","first-page":"539","article-title":"Light chain deposition disease. Experience in our environment","volume":"28","author":"C. Herrera","year":"2008","journal-title":"Nefrologia"},{"key":"37","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2215\/CJN.04590908","article-title":"Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis","volume":"4","author":"C. Hutchison","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"38","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1200\/JCO.2008.19.5370","article-title":"Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma","volume":"27","author":"A. Jakubowiak","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"39","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3324\/haematol.10759","article-title":"Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents","volume":"92","author":"E. Kastritis","year":"2007","journal-title":"Haematologica"},{"key":"40","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.21239","article-title":"Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma","volume":"83","author":"E. Katodritou","year":"2008","journal-title":"American Journal of Hematology"},{"key":"41","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1034\/j.1600-0609.2000.90221.x","article-title":"Renal failure in multiple myeloma: Reversibility and impact on the prognosis","volume":"65","author":"L. Knudsen","year":"2000","journal-title":"European Journal of Haematology"},{"key":"42","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/jmri.21970","article-title":"Estimation of renal function in patients with chronic kidney disease","volume":"30","author":"J. Kooman","year":"2009","journal-title":"Journal of Magnetic Resonance Imaging"},{"key":"43","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00432-008-0470-7","article-title":"Light-chain escape-multiple myeloma\"\u2014An escape phenomenon from plateau phase: Report of the largest patient series using LC-monitoring","volume":"135","author":"A. Kuhnemund","year":"2009","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"44","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/ndt\/gfg567","article-title":"Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient","volume":"19","author":"M. Kunin","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"key":"45","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"R. Kyle","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"46","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/ki.2008.108","article-title":"Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains","volume":"73","author":"N. Leung","year":"2008","journal-title":"Kidney International"},{"key":"47","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification","volume":"139","author":"A. Levey","year":"2003","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1365-2362.2006.01664.x","article-title":"Influence of the parathyroid glands on bone metabolism","volume":"36","author":"H. Malluche","year":"2006","journal-title":"European Journal of Clinical Investigation"},{"key":"49","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.309","article-title":"Renal osteodystrophy in the first decade of the new millennium-analysis of 630 bone biopsies in black and white patients","author":"H. Malluche","year":"2010","journal-title":"Journal of Bone and Mineral Research"},{"key":"50","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/ajkd.2002.32797","article-title":"Nephrotic syndrome after treatment with pamidronate","volume":"39","author":"G. Markowitz","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"key":"51","unstructured":"McCarthy, P.L., Owzar, K., Anderson, K.C., Hofmeister, C.C., & Hurd, D.D. (2010). Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM). Retrieved from <a target=\"_blank\" href='http:\/\/www.asco.org\/ascov2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=43089'>http:\/\/www.asco.org\/ascov2\/Meetings\/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=43089<\/a>"},{"issue":"4","key":"52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1188\/11.S1.CJON.9-23","article-title":"Maintaining bone health in patients with multiple myeloma: Survivorship care plan of the International Myeloma Foundation Nurse Leadership Board","volume":"15","author":"T. Miceli","year":"2011","journal-title":"Clinical Journal of Oncology Nursing"},{"key":"53","unstructured":"Millennium: The Takeda Oncology Company. (2010). <i>Velcade\u00ae (bortezomib)<\/i> [Product information]. Cambridge, MA: Author."},{"key":"54","unstructured":"National Comprehensive Cancer Network. (2010a). Clinical Practice Guidelines in Oncology\u2122: Cancer- and chemotherapy-induced anemia [v.1.2011]. Retrieved from <a target=\"_blank\" href='http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp'>http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp<\/a>"},{"key":"55","unstructured":"National Comprehensive Cancer Network. (2010b). Clinical Practice Guidelines in Oncology\u2122: Multiple myeloma [v.1.2011]. Retrieved from <a target=\"_blank\" href='http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp'>http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp<\/a>"},{"key":"56","unstructured":"National Kidney Foundation. (2010). About chronic kidney disease. Retrieved from <a target=\"_blank\" href='http:\/\/www.kidney.org\/professionals\/KLS\/aboutCKD.cfm'>http:\/\/www.kidney.org\/professionals\/KLS\/aboutCKD.cfm<\/a>"},{"key":"57","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1161\/HYPERTENSIONAHA.108.128413","article-title":"Blood pressure is a major risk factor for renal death: An analysis of 560 352 participants from the Asia-Pacific region","volume":"54","author":"C. O'Seaghdha","year":"2009","journal-title":"Hypertension"},{"key":"58","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/leu.2008.325","article-title":"Treatment of newly diagnosed myeloma","volume":"23","author":"A. Palumbo","year":"2009","journal-title":"Leukemia"},{"key":"59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1525-139X.2006.00181.x","article-title":"Multiple myeloma in end-stage renal disease","volume":"19","author":"J. Penfield","year":"2006","journal-title":"Seminars in Dialysis"},{"key":"60","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"M. Perazella","year":"2008","journal-title":"Kidney International"},{"key":"61","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1016\/B978-0-443-06694-8.50114-7","volume-title":"Abeloff clinical oncology","author":"S. Rajkumar","year":"2008"},{"key":"62","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed myeloma: An open-label randomized controlled trial","volume":"11","author":"S. Rajkumar","year":"2010","journal-title":"Lancet Oncology"},{"key":"63","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.4065\/80.10.1371","article-title":"Multiple myeloma: Diagnosis and treatment","volume":"80","author":"S. Rajkumar","year":"2005","journal-title":"Mayo Clinic Proceedings"},{"key":"64","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"J. San Miguel","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"65","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.transproceed.2007.02.015","article-title":"Recurrent multiple myeloma following renal transplantation: A case report","volume":"39","author":"D. Taheri","year":"2007","journal-title":"Transplantation Proceedings"},{"key":"66","first-page":"1513","volume-title":"Cancer nursing: Principles and practice","author":"J. Tariman","year":"2011"},{"key":"67","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1056\/NEJMp0912328","article-title":"Erythropoiesis-stimulating agents\u2014Time for a re-evaluation","volume":"362","author":"E. Unger","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"68","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.ejca.2004.01.019","article-title":"A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem cell rescue in newly diagnosed patients with stage II\/III multiple myeloma: A prospective randomised phase III study","volume":"40","author":"M. van Agthoven","year":"2004","journal-title":"European Journal of Cancer"},{"key":"69","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa 070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"D. Weber","year":"2007","journal-title":"New England Journal of Medicine"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/6Q6376G6U7RM1021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:48:26Z","timestamp":1763754506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/15\/4\/supplement-august-2011-myeloma-research\/renal-complications"}},"subtitle":["Survivorship Care Plan of the International Myeloma Foundation Nurse Leadership Board"],"short-title":[],"issued":{"date-parts":[[2011,8,1]]},"references-count":69,"journal-issue":{"issue":"0","published-print":{"date-parts":[[2011,8,1]]}},"alternative-id":["6Q6376G6U7RM1021"],"URL":"https:\/\/doi.org\/10.1188\/11.cjon.s1.66-76","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"value":"1092-1095","type":"print"},{"value":"1538-067X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,1]]}}}